Minimally invasive oesophageal adenocarcinoma sentinel node biopsy 4.0

Submission date	Recruitment status No longer recruiting	Prospectively registered		
05/04/2012		☐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
24/07/2012		[X] Results		
Last Edited	Condition category	[] Individual participant data		
06/07/2018	Cancer			

Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-finding-first-lymph-nodes-cancermay-spread-people-having-surgery-cancer-food-pipe

Contact information

Type(s)

Scientific

Contact name

Mr Shajahan Wahed

Contact details

Northern Oesophago-Gastric Cancer Unit Newcastle upon Tyne Hospitals NHS Foundation Trust Royal Victoria Infirmary Newcastle upon Tyne United Kingdom NE1 4LP

shajahan.wahed@nuth.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

11479

Study information

Scientific Title

A prospective, observational study evaluating a minimally invasive technique of identifying the sentinel lymph nodes in patients undergoing surgery for oesophageal adenocarcinoma

Study objectives

Oesophagectomy for cancer carries some of the highest morbidity and mortality risks of any elective surgical procedure. The incidence of oesophageal adenocarcinoma in the Western world is increasing dramatically and shows no signs of slowing down. Endoscopic surveillance of Barrett s oesophagus is also anticipated to increase numbers of patients with high-grade dysplasia of the oesophagus who may require resectional surgery. Studies indicate that the routinely performed extended lymphadenectomy contributes significantly to the risks of surgery. However, determining which patients do not require a radical lymphadenectomy is limited by the relatively low sensitivity and specificity of pre-operative staging investigations. Minimally invasive techniques such as laparoscopic gastric mobilisation and thoracoscopic oesophageal mobilisation have been developed to reduce surgical trauma. These techniques need to be equally as radical in terms of the lymphadenectomy although this can be difficult in some cases. The sentinel lymph node (SLN) concept is that if the first draining lymph node in proximity to a cancer is clear of cancer cells then no other nodes should be involved.

A minimally invasive resection technique coupled to a sensitive minimally invasive SLN assessment could potentially reduce surgical morbidity by identifying patients who could have less extensive surgery without compromising oncological clearance. The SLN status might be the determining factor in deciding whether a patient is indeed suitable for minimally invasive surgery. Furthermore, the technique could also be applied to tailor surgery for those patients having open resections and determine the lymph node status for patients having endoscopic mucosal and submucosal resections for very superficial adenocarcinoma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee North EastCounty Durham & Tees Valley, First MREC 04/10/2011, ref: 11/NE /0262

Study design

Observational trial

Primary study design

Observational

Secondary study design

Other

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Upper Gastro-Intestinal Cancer

Interventions

Laparoscopic gamma probe identification of abdominal sentinel lymph nodes following endoscopic peritumoural technetium injection.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

- 1. Sentinel lymph node identification
- 2. Numbers of patients in whom the abdominal sentinel lymph node is identified after study completion

Secondary outcome measures

No secondary outcome measures

Overall study start date

20/02/2012

Completion date

01/10/2013

Eligibility

Key inclusion criteria

- 1. All patients with potentially curable lower third oesophageal adenocarcinoma or oesophagogastric junction adenocarcinoma planned to undergo curative twostage oesophagectomy
- 2. Male and female participants

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Planned Sample Size: 40; UK Sample Size: 40

Key exclusion criteria

- 1. Incurable disease
- 2. Not suitable for laparoscopy

Date of first enrolment

20/02/2012

Date of final enrolment

01/10/2013

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Royal Victoria Infirmary

Newcastle upon Tyne United Kingdom NE1 4LP

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

Sponsor details

Royal Victoria Infirmary Leazes Wing Queen Victoria Road Newcastle Upon Tyne England United Kingdom NE1 4LP

Sponsor type

Hospital/treatment centre

Website

http://www.newcastle-hospitals.org.uk/

ROR

https://ror.org/05p40t847

Funder(s)

Funder type

University/education

Funder Name

Bupa Foundation

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

Royal College of Surgeons of England

Alternative Name(s)

RCS

Funding Body Type

Private sector organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	results	16/09/2016		No	No